Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with a 25% revenue increase and improved gross margins, which are positive indicators. However, the net loss and negative cash flow, despite improvements, present concerns. The absence of strategic initiatives and operational updates, along with acknowledged risks, tempers enthusiasm. Given the company's market cap of $3.55 billion, the stock is likely to experience neutral movement (-2% to 2%) over the next two weeks due to balanced positive and negative factors.
Key Financial Performance
Revenue $150 million, representing a 25% increase year-over-year, driven by strong demand for our oncology testing services.
Gross Margin 65%, up from 60% in the prior year, due to improved operational efficiencies and cost management.
Operating Expenses $90 million, a 10% increase year-over-year, primarily due to investments in R&D and expansion of our commercial team.
Net Loss $30 million, compared to $40 million in the prior year, reflecting improved revenue growth and cost control measures.
Cash Flow from Operations Negative $10 million, an improvement from negative $20 million in the prior year, attributed to better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company acknowledges material risks and uncertainties that could cause actual results or events to differ from anticipated outcomes. This includes risks tied to forward-looking statements made during the call.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AmirAli Talasaz
Arias Stifel
Babington Wolfe
BofA Securities
Brandon Couillard
Canaccord Genuity
Chairman AmirAli
Colleen Babington
Couillard Wells
Director Bell
Division Arias
Division Bradley
Division Brandon
Division Colleen
Division PM
Division Patrick
Division Ryskin
Division Tycho
EDT afternoon
Fargo Securities
Guardant Health
Helmy Eltoukhy
Kyle Mikson
LLC Research
LLC Sebastian
Mikson Canaccord
Officer Massaro
PM EDT
Patrick Donnelly
Relations Helmy
Relations statement
Research Division
Research LLC
Securities LLC
GH Transcript
Guardant Health, Inc. (GH) Q1 2026 Earnings Call Transcript
Unknown5-8
The earnings call highlights strong financial performance with a 25% revenue increase and improved gross margins, which are positive indicators. However, the net loss and negative cash flow, despite improvements, present concerns. The absence of strategic initiatives and operational updates, along with acknowledged risks, tempers enthusiasm. Given the company's market cap of $3.55 billion, the stock is likely to experience neutral movement (-2% to 2%) over the next two weeks due to balanced positive and negative factors.
Guardant Health, Inc. (GH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Neutral3-11
Guardant Health, Inc. (GH) Q4 2025 Earnings Call Transcript
Positive2-19
The earnings call summary and Q&A section highlight strong revenue growth, improved guidance, and strategic partnerships, which are positive indicators for stock price movement. Raised revenue guidance, oncology revenue growth, and Shield's commercial expansion are significant positives. The Q&A section reveals optimism about product differentiation and regulatory strategies, although some management responses were vague. The market cap suggests moderate volatility, leading to a positive stock price movement prediction of 2% to 8% over the next two weeks.
Guardant Health, Inc. (GH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
GH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
